FURTHER EVIDENCE THAT NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS A THROMBOPHILIC STATE: PLASMINOGEN ACTIVATOR INHIBITOR ONE LEVELS ARE SIGNIFICANTLY ELEVATED IN LIVER TRANSPLANT CANDIDATES WITH DECOMPENSATED NONALCOHOLIC STEATOHEPATITIS (NASH) CIRRHOSIS

被引：0
|
作者：
Stine, Jonathan [1 ]
Baragona, Allison [2 ]
Hummer, Breianna [1 ]
Rivas, Gloriany [1 ]
Bezinover, Dmitri [3 ]
Kadry, Zakiyah [4 ]
机构：
[1] Penn State Univ, Milton S Hershey Med Ctr, Div Gastroenterol & Hepatol, Dept Med, University Pk, PA 16802 USA
[2] Penn State Univ, Milton S Hershey Med Ctr, Gastroenterol & Hepatol, Dept Med, University Pk, PA 16802 USA
[3] Penn State Univ, Milton S Hershey Med Ctr, Dept Anesthesia, University Pk, PA 16802 USA
[4] Penn State Univ, University Pk, PA 16802 USA
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2290
引用
收藏
页码：1346A / 1346A
页数：1
相关论文
共 50 条
  • [41] The Prevalence and Severity of Nonalcoholic Fatty Liver Disease Is High Among Primary Caregivers of Potential Liver Transplant Recipients with Cirrhosis Resulting from Nonalcoholic Steatohepatitis
    Patel, Samarth
    Carbone, Salvatore
    Siddiqui, Mohammad Bilal
    Patel, Vaishall B.
    Matherly, Scott C.
    Driscoll, Carolyn J.
    Stravitz, R. Todd
    Lee, Hannah
    Sanyal, Arun J.
    Luketic, Velimir A.
    Sterling, Richard K.
    Siddiqui, Mohammad Shadab
    HEPATOLOGY, 2018, 68 : 1313A - 1314A
  • [42] Concomitance of nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH) is associated with the histological severity in Hepatitis B virus-infected liver
    Aizawa, Nobuhiro
    Enomoto, Hirayuki
    Miyamoto, Yuho
    Ishii, Noriko
    Hasegawa, Kunihiro
    Yuri, Yukihisa
    Takata, Ryo
    Yoh, Kazunori
    Ishii, Akio
    Nakano, Chikage
    Sakai, Yoshiyuki
    Takashima, Tomoyuki
    Ikeda, Naoto
    Nishimura, Takashi
    Iwata, Yoshinori
    Nishikawa, Hiroki
    Iijima, Hiroko
    Nishiguchi, Shuhei
    HEPATOLOGY, 2016, 64 : 306A - 307A
  • [43] Higher Rates of Disease Progression among Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) Patients with Advanced Fibrosis (AF) and Diabetes Mellitus (DM)
    Younossi, Zobair
    Kachru, Nandita
    Shreay, Sanatan
    Loomba, Rohit
    DIABETES, 2019, 68
  • [44] Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
    Terai, Shuji
    Buchanan-Hughes, Amy
    Ng, Alvin
    Lee, I-Heng
    Hasegawa, Ken
    JOURNAL OF GASTROENTEROLOGY, 2021, 56 (03) : 274 - 284
  • [45] The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Among Patients with Psoriasis and Psoriatic Arthritis in a Tertiary Care Dermatology and Rheumatology Clinic
    Fewell, Allyson
    Lamb, Paul B.
    Roberts, Katharine K.
    Battafarano, Daniel
    Owens, Nicole M.
    Harrison, Stephen A.
    HEPATOLOGY, 2012, 56 : 897A - 897A
  • [46] Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
    Shuji Terai
    Amy Buchanan-Hughes
    Alvin Ng
    I-Heng Lee
    Ken Hasegawa
    Journal of Gastroenterology, 2021, 56 : 274 - 284
  • [47] Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease
    Sjowall, Christopher
    Martinsson, Klara
    Cardell, Kristina
    Ekstedt, Mattias
    Kechagias, Stergios
    TRANSLATIONAL RESEARCH, 2015, 165 (06) : 658 - 666
  • [48] Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome
    de Larranaga, Gabriela
    Wingeyer, Silvia Peres
    Graffigna, Mabel
    Belli, Susana
    Bendezu, Karla
    Alvarez, Silvia
    Levalle, Oscar
    Fainboim, Hugo
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2008, 14 (03) : 319 - 324
  • [49] EVALUATION OF FIBROSCAN-AST (FASTTM) SCORE FOR THE DETECTION OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) PATIENTS WHO ARE AT-RISK FOR FIBROTIC NONALCOHOLIC STEATOHEPATITIS (NASH)
    Mitchell, Brittany
    Fahad, Hamna
    Sarmini, Muhammad Talal
    McCullough, Arthur
    GASTROENTEROLOGY, 2020, 158 (06) : S1409 - S1409
  • [50] Increasing Healthcare Resource Utilization (HCRU) and Costs Associated with Advanced Liver Disease - a Multivariate Analyses of Real-World Medicare Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) Patients
    Gordon, Stuart C.
    Fraysse, Jeremy
    Li, Suying
    Wong, Robert J.
    HEPATOLOGY, 2018, 68 : 573A - 573A
12345